RIGEL PHARMACEUTICALS, INC. (RIGL) Spending and interest coverage
- R&D / revenue · 12 months: Value 15.78%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.93%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 15.78% | Research and development expense / revenue. Period ending 2026-06-30. $43.67M ÷ $276.79M × 100 ≈ 15.78% |
| Stock-based compensation / revenue · 12 months | 5.93% | Share-based compensation / revenue. Period ending 2026-06-30. $16.41M ÷ $276.79M × 100 ≈ 5.93% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 43.67M USD | Research and Development Expense |
| Revenue | 276.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 16.41M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 87.05M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.67M | $276.79M | $16.41M | $87.05M | (m) | 15.78% | 5.93% | (m) | (m) |
| 2026-03-31 | $36.53M | $299.77M | $12.84M | $124.58M | (m) | 12.19% | 4.28% | (m) | (m) |
| 2025-12-31 | $33.30M | $294.28M | $12.71M | $125.47M | (m) | 11.31% | 4.32% | (m) | (m) |
| 2025-09-30 | (m) | $282.08M | $12.05M | $118.95M | $7.58M | (m) | 4.27% | 15.70× | Reported |
| 2025-06-30 | (m) | $267.92M | $11.33M | $104.59M | $7.74M | (m) | 4.23% | 13.51× | Reported |
| 2025-03-31 | (m) | $203.08M | $10.58M | $43.93M | $7.90M | (m) | 5.21% | 5.56× | Reported |
| 2024-12-31 | (m) | $179.28M | $12.39M | $24.19M | $7.92M | (m) | 6.91% | 3.06× | Reported |
| 2024-09-30 | (m) | $157.47M | $12.24M | $9.50M | $7.87M | (m) | 7.77% | 1.21× | Reported |
| 2024-06-30 | (m) | $130.30M | $11.54M | $-9.02M | $7.71M | (m) | 8.85% | -1.17× | Reported |
| 2024-03-31 | (m) | $120.35M | $11.18M | $-14.73M | $7.54M | (m) | 9.29% | -1.95× | Reported |
| 2023-12-31 | (m) | $116.88M | $8.81M | $-20.49M | $6.87M | (m) | 7.53% | -2.98× | Reported |
| 2023-09-30 | (m) | $132.37M | $10.95M | $-20.38M | $6.07M | (m) | 8.27% | -3.36× | Reported |
| 2023-06-30 | (m) | $126.64M | $11.72M | $-34.32M | $5.00M | (m) | 9.25% | -6.86× | Reported |
| 2023-03-31 | (m) | $129.58M | $11.94M | $-42.01M | $3.71M | (m) | 9.21% | -11.34× | Reported |
| 2022-12-31 | (m) | $120.24M | $12.38M | $-55.55M | $3.71M | (m) | 10.30% | -14.99× | Reported |
| 2022-09-30 | (m) | $89.37M | $10.64M | $-79.05M | $3.90M | (m) | 11.91% | -20.27× | Reported |
| 2022-06-30 | (m) | $88.51M | $10.14M | $-80.43M | $4.39M | (m) | 11.46% | -18.32× | Reported |
| 2022-03-31 | (m) | $84.95M | $10.05M | $-80.51M | $5.58M | (m) | 11.83% | -14.43× | Reported |
| 2021-12-31 | (m) | $149.24M | $9.49M | $-12.50M | $4.86M | (m) | 6.36% | -2.57× | Reported |
| 2021-09-30 | (m) | $147.28M | $8.78M | $-9.90M | $3.99M | (m) | 5.96% | -2.48× | Reported |
| 2021-06-30 | (m) | $144.12M | $8.46M | $-3.90M | $3.10M | (m) | 5.87% | -1.26× | Reported |
| 2021-03-31 | (m) | $133.88M | $7.91M | $-8.24M | $1.70M | (m) | 5.91% | -4.86× | Reported |
| 2020-12-31 | (m) | $108.62M | $7.30M | $-28.97M | $1.35M | (m) | 6.72% | -21.41× | Reported |
| 2020-09-30 | (m) | $105.57M | $7.08M | $-27.48M | $1.25M | (m) | 6.70% | -21.97× | Reported |
| 2020-06-30 | (m) | $108.04M | $7.29M | $-25.74M | $830.00K | (m) | 6.75% | -31.01× | Reported |
| 2020-03-31 | (m) | $102.42M | $8.19M | $-29.69M | (m) | (m) | 7.99% | (m) | (m) |
| 2019-12-31 | (m) | $59.29M | $9.12M | $-69.09M | $335.00K | (m) | 15.37% | -206.24× | Reported |
| 2019-09-30 | (m) | $81.75M | $9.76M | $-49.22M | (m) | (m) | 11.94% | (m) | (m) |
| 2019-06-30 | (m) | $65.75M | $10.66M | $-61.55M | (m) | (m) | 16.21% | (m) | (m) |
| 2019-03-31 | (m) | $57.13M | $9.12M | $-66.33M | (m) | (m) | 15.96% | (m) | (m) |
| 2018-12-31 | (m) | $44.51M | $7.70M | $-72.68M | (m) | (m) | 17.31% | (m) | (m) |
| 2018-09-30 | (m) | (m) | $8.71M | $-101.43M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $6.58M | $-94.92M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $6.57M | $-88.15M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $5.99M | $-79.62M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $5.59M | $-69.19M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $5.94M | $-74.07M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $6.85M | $-68.38M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $7.33M | $-69.74M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | $6.29M | $-66.70M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $6.89M | $-50.74M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $6.79M | $-51.07M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $7.40M | $-51.74M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | $8.99M | $-61.36M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $9.25M | $-75.62M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $9.48M | $-87.11M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | $9.79M | $-91.25M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $8.14M | $-85.83M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $8.12M | $-88.72M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $7.74M | $-86.14M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $7.17M | $-89.47M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $8.87M | $-98.14M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $10.05M | $-99.78M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $11.31M | $-101.78M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $12.62M | $-99.38M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | $12.39M | $-99.67M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $12.24M | $-92.14M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | $12.43M | $-88.82M | $14.00K | (m) | (m) | -6344.14× | Reported |
| 2011-12-31 | (m) | (m) | $13.17M | $-86.37M | $25.00K | (m) | (m) | -3454.72× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $16.44M | $35.32M | $91.00K | (m) | (m) | 388.10× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $13.44M | $-112.04M | $203.00K | (m) | (m) | -551.91× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |